US 12,479,839 B2
Crystalline form of ATR inhibitor and use thereof
Jian Wang, Shanghai (CN); Ting Yao, Shanghai (CN); Wenyuan Qian, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to Wuxi Biocity Biopharmaceutics Co., Ltd., Jiangsu (CN)
Appl. No. 17/632,823
Filed by Wuxi Biocity Biopharmaceutics Co., Ltd., Jiangsu (CN)
PCT Filed Aug. 6, 2020, PCT No. PCT/CN2020/107474
§ 371(c)(1), (2) Date Feb. 4, 2022,
PCT Pub. No. WO2021/023272, PCT Pub. Date Feb. 11, 2021.
Claims priority of application No. 201910722102.7 (CN), filed on Aug. 6, 2019.
Prior Publication US 2022/0281858 A1, Sep. 8, 2022
Int. Cl. C07D 413/14 (2006.01)
CPC C07D 413/14 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystal form of a compound of formula (I):

OG Complex Work Unit Chemistry
which is selected from the group consisting of:
(1) Crystal Form A, wherein,
the Crystal Form A has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 20 angles: 8.10±0.20°, 18.33±0.20° and 22.63±0.20°;
(2) Crystal Form B, wherein,
the Crystal Form B has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 20 angles: 8.45±0.20°, 10.87±0.20° and 20.56±0.20°.
 
19. A method for treating colorectal cancer, comprising administering the crystal form according to claim 1 to a subject in need thereof.